Daily15d
Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines
Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...
Pharmabiz16d
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines
Ribociclib (Kisqali) is the only CDK4/6i recommended for ... Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four ...
BioSpace21d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 ...
Yahoo Finance24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...
Le Lézard24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
will be eligible for adjuvant treatment with Kisqali ® (ribociclib) in combination with an aromatase inhibitor 1 Recommendation is based on the Phase III NATALEE trial, where Kisqali added to ...